Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

156 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM. Hille CJ, et al. Among authors: crossman ar. Exp Neurol. 2001 Nov;172(1):189-98. doi: 10.1006/exnr.2001.7763. Exp Neurol. 2001. PMID: 11681851
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease.
Maneuf YP, Duty S, Hille CJ, Crossman AR, Brotchie JM. Maneuf YP, et al. Among authors: crossman ar. Exp Neurol. 1996 May;139(1):12-6. doi: 10.1006/exnr.1996.0075. Exp Neurol. 1996. PMID: 8635558
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J. Fox S, et al. Mov Disord. 2004 May;19(5):554-60. doi: 10.1002/mds.10693. Mov Disord. 2004. PMID: 15133820 Clinical Trial.
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M. Millan MJ, et al. J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. doi: 10.1124/jpet.103.062414. Epub 2004 Feb 20. J Pharmacol Exp Ther. 2004. PMID: 14978195
Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats.
Ismayilova N, Crossman A, Verkhratsky A, Brotchie J. Ismayilova N, et al. Eur J Pharmacol. 2004 Aug 23;497(2):187-95. doi: 10.1016/j.ejphar.2004.06.030. Eur J Pharmacol. 2004. PMID: 15306204
Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease.
Scheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, Ravenscroft P, Guigoni C, Crossman AR, Hill M, Bezard E. Scheller D, et al. Among authors: crossman ar. Exp Neurol. 2007 Feb;203(2):415-22. doi: 10.1016/j.expneurol.2006.08.026. Epub 2006 Oct 12. Exp Neurol. 2007. PMID: 17045989
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C, Crossman AR, Ravenscroft P. Kobylecki C, et al. Among authors: crossman ar. Exp Neurol. 2013 Sep;247:476-84. doi: 10.1016/j.expneurol.2013.01.019. Epub 2013 Jan 27. Exp Neurol. 2013. PMID: 23360800
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Savola JM, et al. Among authors: crossman ar. Mov Disord. 2003 Aug;18(8):872-83. doi: 10.1002/mds.10464. Mov Disord. 2003. PMID: 12889076
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Segovia G, Mora F, Crossman AR, Brotchie JM. Segovia G, et al. Among authors: crossman ar. Mov Disord. 2003 Feb;18(2):138-49. doi: 10.1002/mds.10312. Mov Disord. 2003. PMID: 12539206
156 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback